Answer
Fatal and serious infections, including opportunistic infections and sepsis, have been reported in patients treated with loncastuximab tesirine (Zynlonta).
Sources for this answer
- Zynlonta, 10mg, powder for concentrate for solution for infusionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 6Document updated
Sources checked